Changes for page Ajanta Pharma Ltd

Last modified by Asif Farooqui on 2021/03/15 15:40
From version < 2.2 >
edited by Asif Farooqui
on 2020/10/07 20:49
To version < 3.1 >
edited by Asif Farooqui
on 2020/10/08 14:49
< >
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -72,10 +72,8 @@
72 72  
73 73  == International business ==
74 74  
75 -Total sales from international business for FY 2020 stood at H 1,790 cr. against H 1,324 cr. in the previous year, a growth of 35%. It was primarily backed by robust growth of 82% in the US market and strong growth in branded generics at 27% in Asia and 14% in Africa.
75 +Total sales from international business for FY 2020 stood at H 1,790 cr. against H 1,324 cr. in the previous year, a growth of 35%. It was primarily backed by robust growth of 82% in the US market and strong growth in branded generics at 27% in Asia and 14% in Africa. Company’s exports revenues are contributed by well-diversified markets, avoiding over dependence on any single market.
76 76  
77 -As explained in Exhibit 4 and Exhibit 5, company’s exports revenues are contributed by well-diversified markets, avoiding over dependence on any single market.
78 -
79 79  = Financial highlight =
80 80  
81 81  April 30, 2020 Ajanta Pharma Ltd. reported performance for the 4 th quarter & financial year ended 31 st March 2019.{{footnote}}http://www.ajantapharma.com/AdminData/Results/PressReleaseandResultQ4FY2019.pdf{{/footnote}}
XWiki.XWikiComments[0]
Author
... ... @@ -1,0 +1,1 @@
1 +XWiki.AsifF
Comment
... ... @@ -1,0 +1,3 @@
1 +AJANTPHARM
2 +Recent investor presentation
3 +http://ajantapharma.com/AdminData/InvesterPresentation/InvestorPresentationQ1FY2021.pdf
Date
... ... @@ -1,0 +1,1 @@
1 +2020-10-07 20:49:17.820
This site is funded and maintained by Fintel.io